blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3442529

EP3442529 - COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF LUNG CANCER [Right-click to bookmark this link]
Former [2019/08]COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER
[2020/22]
StatusNo opposition filed within time limit
Status updated on  02.04.2022
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  23.04.2021
FormerGrant of patent is intended
Status updated on  27.10.2020
FormerExamination is in progress
Status updated on  08.10.2020
FormerGrant of patent is intended
Status updated on  27.05.2020
FormerExamination is in progress
Status updated on  23.08.2019
FormerRequest for examination was made
Status updated on  18.01.2019
FormerThe international publication has been made
Status updated on  20.10.2017
Formerunknown
Status updated on  26.04.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2019/08]
Inventor(s)01 / BECKMANN, Richard Paul
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis Indiana 46206-6288 / US
02 / PATEL, Bharvin Kumar
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis Indiana 46206-6288 / US
 [2019/08]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2019/08]
Application number, filing date17717990.005.04.2017
[2019/08]
WO2017US26134
Priority number, dateUS201662321311P12.04.2016         Original published format: US 201662321311 P
[2019/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017180389
Date:19.10.2017
Language:EN
[2017/42]
Type: A1 Application with search report 
No.:EP3442529
Date:20.02.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.10.2017 takes the place of the publication of the European patent application.
[2019/08]
Type: B1 Patent specification 
No.:EP3442529
Date:26.05.2021
Language:EN
[2021/21]
Search report(s)International search report - published on:EP19.10.2017
ClassificationIPC:A61K31/444, A61K31/506, A61K31/55, A61P35/00, A61P35/02
[2019/08]
CPC:
A61K31/55 (EP,US); A61K31/444 (EP,RU); A61K31/4745 (US);
A61K31/506 (EP,US); A61P35/00 (EP,RU,US); A61P35/02 (EP);
A61P35/04 (US); A61P43/00 (EP) (-)
C-Set:
A61K31/444, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/55, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/08]
Extension statesBA12.11.2018
ME12.11.2018
Validation statesMA12.11.2018
MD12.11.2018
TitleGerman:KOMBINATIONSTHERAPIE MIT NOTCH- UND CDK4/6-INHIBITOREN ZUR BEHANDLUNG VON LUNGENKREBS[2020/22]
English:COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF LUNG CANCER[2020/22]
French:TRAITEMENT D'ASSOCIATION À BASE D'INHIBITEURS DE NOTCH ET DE CDK4/6 POUR LE TRAITEMENT DU CANCER DU POUMON[2020/22]
Former [2019/08]KOMBINATIONSTHERAPIE MIT NOTCH- UND CDK4/6-INHIBITOREN ZUR BEHANDLUNG VON KREBS
Former [2019/08]COMBINATION THERAPY WITH NOTCH AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER
Former [2019/08]TRAITEMENT D'ASSOCIATION À BASE D'INHIBITEURS DE NOTCH ET DE CDK4/6 POUR LE TRAITEMENT DU CANCER
Entry into regional phase12.11.2018National basic fee paid 
12.11.2018Designation fee(s) paid 
12.11.2018Examination fee paid 
Examination procedure12.11.2018Examination requested  [2019/08]
12.11.2018Date on which the examining division has become responsible
13.06.2019Amendment by applicant (claims and/or description)
27.08.2019Despatch of a communication from the examining division (Time limit: M06)
06.03.2020Reply to a communication from the examining division
28.05.2020Communication of intention to grant the patent
06.10.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.10.2020Communication of intention to grant the patent
08.03.2021Fee for grant paid
08.03.2021Fee for publishing/printing paid
08.03.2021Receipt of the translation of the claim(s)
Opposition(s)01.03.2022No opposition filed within time limit [2022/18]
Fees paidRenewal fee
12.11.2018Renewal fee patent year 03
21.04.2020Renewal fee patent year 04
15.04.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.04.2017
AL26.05.2021
AT26.05.2021
CY26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
MC26.05.2021
MK26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
TR26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
[2024/29]
Former [2024/22]HU05.04.2017
AL26.05.2021
AT26.05.2021
CY26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
MC26.05.2021
MK26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2024/20]HU05.04.2017
AL26.05.2021
AT26.05.2021
CY26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
MC26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2024/18]HU05.04.2017
AL26.05.2021
AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
MC26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2023/06]AL26.05.2021
AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
MC26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/29]AL26.05.2021
AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SI26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/26]AL26.05.2021
AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/23]AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/10]AT26.05.2021
CZ26.05.2021
DK26.05.2021
EE26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
PT27.09.2021
IS22.12.2021
Former [2022/09]AT26.05.2021
CZ26.05.2021
DK26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RO26.05.2021
RS26.05.2021
SE26.05.2021
SK26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/08]AT26.05.2021
CZ26.05.2021
DK26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RS26.05.2021
SE26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/07]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RS26.05.2021
SE26.05.2021
SM26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2022/04]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
NL26.05.2021
PL26.05.2021
RS26.05.2021
SE26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2021/52]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
PL26.05.2021
RS26.05.2021
SE26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2021/51]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
RS26.05.2021
SE26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
IS26.09.2021
PT27.09.2021
Former [2021/50]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
SE26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
PT27.09.2021
Former [2021/49]AT26.05.2021
FI26.05.2021
HR26.05.2021
LT26.05.2021
LV26.05.2021
SE26.05.2021
BG26.08.2021
NO26.08.2021
GR27.08.2021
Former [2021/47]AT26.05.2021
FI26.05.2021
LT26.05.2021
BG26.08.2021
Former [2021/46]AT26.05.2021
FI26.05.2021
LT26.05.2021
Cited inInternational search[YD]WO2010075074  (LILLY CO ELI [US], et al) [YD] 1-6 * page 3, lines 19-24 * * page 7, lines 5-8 * * page 52, line 24 - page 54, line 4 * * claims 13, 19 *;
 [Y]WO2012097039  (LILLY CO ELI [US], et al) [Y] 7,8 * page 30, lines 17-24 * * page 31, lines 7-12 * * page 36, lines 11-19 * * page 37, lines 3-12 * * claims 1, 6, 10 *;
 [YD]WO2013016081  (LILLY CO ELI [US], et al) [YD] 1-8 * page 33, line 26 - page 34, line 13 * * pages 40-41; table 2 * * page 41, lines 3-6 * * claims 1, 5 *;
 [Y]  - Mark H Bender, "Novel inhibitor of Notch signaling for the treatment of cancer", Cancer Res April 15, 2013 73, (20130415), page 1131, URL: http://cancerres.aacrjournals.org/content/73/8_Supplement/1131, (20160603), XP055277786 [Y] 1-8 * the whole document *
 [Y]  - Anonymous, "NCT02079636 on 2016_02_03: A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)", ClinicalTrials.gov Archive, (20160203), URL: https://clinicaltrials.gov/archive/NCT02079636/2016_02_03, (20170626), XP055384957 [Y] 1-8 * abstract * * page 2, paragraph l * * page 4, paragraph 2 *
 [XP]  - Anonymous, "NCT02784795 on 2016_05_26: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", ClinicalTrials.gov Archive, (20160526), URL: https://clinicaltrials.gov/archive/NCT02784795/2016_05_26, (20170626), XP055384918 [XP] 1,3,5,7 * the whole document *
 [YP]  - Anonymous, "Notch Inhibitor Shows Modest Efficacy", Cancer Discovery, (20161214), pages 1 - 3, URL: http://cancerdiscovery.aacrjournals.org/content/early/2016/12/13/2159-8290.CD-NB2016-159, (20170629), XP055386303 [YP] 1,3,5,7 * the whole document *
Examination   - Cyriac Kandoth ET AL, "Mutational landscape and significance across 12 major cancer types", Nature, London, (20131001), vol. 502, no. 7471, doi:10.1038/nature12634, ISSN 0028-0836, pages 333 - 339, XP055614322

DOI:   http://dx.doi.org/10.1038/nature12634
by applicantWO2010075074
 WO2013016081
    - JOSHI ET AL., BLOOD, (2009), vol. 113, no. 8, pages 1689 - 1698
    - RAO ET AL., CANCER RES., (2009), vol. 69, no. 7, pages 3060 - 3068
    - HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS
    - S.M. BERGE ET AL., "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, (197701), vol. 66, no. 1, doi:doi:10.1002/jps.2600660104, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - HOLFORD; SCHEINER, CLIN. PHARMACOKINET., (1981), vol. 6, pages 429 - 453
    - LOEWE; MUISCHENK, ARCH. EXP. PATHOL. PHARMACOL., (1926), vol. 114, pages 313 - 326
    - CHOU; TALALAY, ADV. ENZYME REGUL., (1984), vol. 22, pages 27 - 55
    - EISENHAUER ET AL., EUROPEAN JOURNAL OF CANCER, (2009), vol. 45, pages 228 - 247
    - EISENHAUER ET AL., EUR. J. CANCER, (2009), vol. 45, no. 2, pages 228 - 247
    - CHOI ET AL., J. CLIN. ONCOL., (2007), vol. 25, no. 13, pages 1753 - 1759
    - WEN ET AL., J. CLIN. ONCOL., (2010), vol. 28, no. 11, pages 1963 - 1972
    - OKEN ET AL., AM. J. CLIN. ONCOL., (1982), vol. 5, pages 649 - 655
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.